Solid Biosciences Company Insiders

SLDB Stock  USD 4.60  0.10  2.13%   
Solid Biosciences employs about 100 people. The company is managed by 21 executives with a total tenure of roughly 14 years, averaging almost 0.0 years of service per executive, having 4.76 employees per reported executive. Analysis of Solid Biosciences' management performance can provide insight into the company performance.
Ilan Ganot  CEO
CEO, Co-Founder, Director
Andrey Zarur  Chairman
Chairman of the Board, Co-Founder
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Solid Biosciences Management Team Effectiveness

The company has return on total asset (ROA) of (0.4586) % which means that it has lost $0.4586 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9457) %, meaning that it created substantial loss on money invested by shareholders. Solid Biosciences' management efficiency ratios could be used to measure how well Solid Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.

Solid Biosciences Workforce Comparison

Solid Biosciences LLC is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,349. Solid Biosciences holds roughly 100.0 in number of employees claiming about 4% of equities under Health Care industry.

Solid Biosciences Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Solid Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Solid Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Solid Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Solid Biosciences Notable Stakeholders

A Solid Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Solid Biosciences often face trade-offs trying to please all of them. Solid Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Solid Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Alexander CumboCEO PresidentProfile
Ilan GanotCEO, Co-Founder, DirectorProfile
Andrey ZarurChairman of the Board, Co-FounderProfile
Gilad HayeemPresident Co-Founder, DirectorProfile
Kevin CFACFO TreasurerProfile
Nicole AndersonDirector CommunicationsProfile
Matthew ArnoldIndependent DirectorProfile
Gabriel MDChief OfficerProfile
Shuli MDHead DevelopmentProfile
Paul HerzichChief OfficerProfile
Caitlin LowieVP IRProfile
Allison JDSenior ResourcesProfile
Carl MorrisChief Scientific OfficerProfile
ACA ACAEx ChairProfile
Erin BrennanChief SecProfile
JD HowtonChief OfficerProfile
MBA MBATreasurer CFOProfile
CPA ACAExecutive ChairProfile
Stephen MBATreasurer OfficerProfile
Annie GanotCoFounder AdvocacyProfile
Jessie HanrahanChief OfficerProfile

About Solid Biosciences Management Performance

The success or failure of an entity such as Solid Biosciences LLC often depends on how effective the management is. Solid Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Solid management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Solid management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Solid Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people.
Please note, the presentation of Solid Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Solid Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Solid Biosciences' management manipulating its earnings.

Solid Biosciences Workforce Analysis

Traditionally, organizations such as Solid Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Solid Biosciences within its industry.

Solid Biosciences Manpower Efficiency

Return on Solid Biosciences Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.2M
Net Loss Per Executive5.9M
Working Capital Per Employee1.3M
Working Capital Per Executive6M

Complementary Tools for Solid Stock analysis

When running Solid Biosciences' price analysis, check to measure Solid Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Solid Biosciences is operating at the current time. Most of Solid Biosciences' value examination focuses on studying past and present price action to predict the probability of Solid Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Solid Biosciences' price. Additionally, you may evaluate how the addition of Solid Biosciences to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing